Management of hypertension in the very elderly patient

Hypertension

Volumn 44, Issue 6, 2004, Pages 800-804

  Elliott, William J ^a,b  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antihypertensive therapy; Clinical trials; Elderly; Population

Indexed keywords

ACETYLSALICYLIC ACID; CHLORTALIDONE; DIURETIC AGENT;

AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; HEART FAILURE; HUMAN; HYPERTENSION; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; STROKE; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DECISION MAKING; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE;

EID: 9644284316     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000146909.69161.8c     Document Type: Article

References (39)

1. National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
2. Ezzati M, Lopez AD, Rodgers A, van der Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360.
3. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaborative. Lancet. 2002;360:1903-1913.
4. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. J Am Med Assoc. 2002;287:1003-1010.
5. Meyer J. Age: 2000 (a Census 2000 brief; C2KBR/01-12). US Department of Commerce: Economics and Statistics Administration: US Census Bureau, October 2001. Accessed at www.census.gov/prod/ 2001pubs/c2kbr01-12.pdf on 15 AUG 04 at 16:40 CDT.
6. US Census Bureau. International Database. Found on the internet at www.census.gov/cgi-bin/ipc/idbsum?cty=US. Accessed 15 AUG 04 at 20:17 CDT.
7. Kostis JB. Treatment of octogenarians: should we and how? (part II). J Clin Hypertens. 2004;6:270-273.
8. Phillips RA. Treatment of octogenarians: should we and how? (part I). J Clin Hypertens. 2004;6:267-270.
9. Jackson P. The influence of absolute cardiovascular risk, patient utilities and cost on the decision to treat hypertension: a Markov decision analysis. J Hypertens. 2003;21:1631-1634.
10. Kochanek KD, Smith BL. Deaths: preliminary data for 2002. Natl Vital Stat Rep. 2004;52:1-47.
11. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(suppl 1):S1-S290.
12. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 01 March 2003. J Hypertens. 2003;21:1055-1076.
13. Wilking SV, Belanger A, Kannel WB, D'Agostino RB, Steel K. Determinants of isolated systolic hypertension. J Am Med Assoc. 1988;260:3451-3455.
14. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. J Am Med Assoc. 2003;290:199-203.
15. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertensino among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869-874.
16. SHEP Cooperative Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. J Am Med Assoc. 1991;265:3255-3264.
17. Perry HM Jr., Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, Kuller L, Pressel S, Stamler J, Probstfield JL. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc. 2000;284:465-471.
18. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Borge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. J Am Med Assoc. 1997;278:212-216.
19. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Flechter AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;360:757-764.
20. Liu L, Wang J, Gong L, Liu G, Staessen JA; for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-1829.
21. Gueyffier F, Bulpitt C, Boissel J-P, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J. Antihypertensive drugs in very old people: a subgroup metaanalysis of randomized controlled trials. INDANA Group. Lancet. 1999;353:793-796.
22. Wang J-G, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med. 2000;160:211-220.
23. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
24. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Biossel J-P, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard R. Risks of untreated and treated isolated systolic hypertension in the elderly: metaanalysis of outcome trials. Lancet. 2000;355:865-872.
25. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindhohn LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H. LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) Substudy. J Am Med Assoc. 2002;288:1491-1498.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. 2002;288:2981-2997.
27. Bulpitt C, Beckett N, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thikj L. Results of the pilot study for the Hypertension in the Very Elderly Trial (HYVET-pilot) [abstract]. J Hypertens. 2002;20(suppl 4):S5.
28. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, Nachev C, Potter J, Sever P, Staessen J, Swift C, Tuomilehto J. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging. 2001;18:151-164.
29. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet. 1998;352:1347-1351.
30. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOP Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
31. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet. 2003;362:1527-1535.
32. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network metaanalysis. J Am Med Assoc. 2003;289:2534-2544.
33. Elliott WJ. Calcium channel blockers and their role in stroke prevention. Presented at the 19th Annual Scientific Meeting of the American Society of Hypertension, New York, NY: May 19, 2004.
34. Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, Farber M, Payne G, Probstfield J, Ward H. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials. 2001;22:674-686.
35. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone. Evidence supporting their interchangeability. Hypertension. 2004;43:4-9.
36. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low dose diuretic therapies. J Am Med Assoc. 2004;292:43-44.
37. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
38. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgon TO, West MJ. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
39. Beckett NS, Connor M, Sadler JD, Fletcher AE, Bulpitt CJ. Orthostatic fall in blood pressure in the very elderly hypertensive: results from the Hypertension in the Very Elderly Trial (HYVET) pilot. J Hum Hypertension. 1999;13:839-840.